Anavex Life Sciences Corp. (NASDAQ:AVXL – Get Free Report) has earned an average recommendation of “Hold” from the five analysts that are covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $21.33.
Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Anavex Life Sciences in a research report on Tuesday, September 8th.
Get Our Latest Stock Analysis on AVXL
Institutional Investors Weigh In On Anavex Life Sciences
Anavex Life Sciences Trading Down 9.6%
Anavex Life Sciences stock opened at $1.65 on Thursday. The company has a fifty day simple moving average of $2.79 and a 200-day simple moving average of $2.88. The stock has a market cap of $152.49 million, a P/E ratio of -10.97 and a beta of 1.17. Anavex Life Sciences has a 12-month low of $1.63 and a 12-month high of $10.38.
Anavex Life Sciences (NASDAQ:AVXL – Get Free Report) last posted its earnings results on Tuesday, August 25th. The biotechnology company reported $0.08 EPS for the quarter, beating the consensus estimate of ($0.08) by $0.16. As a group, sell-side analysts forecast that Anavex Life Sciences will post -0.33 earnings per share for the current fiscal year.
Key Stories Impacting Anavex Life Sciences
Here are the key news stories impacting Anavex Life Sciences this week:
- Neutral Sentiment: Several firms, including Rosen Law Firm announcement Rosen Law Firm, announced that a class action has been filed on behalf of investors who purchased AVXL securities between November 26, 2025, and August 28, 2026. The firms are seeking investors who may wish to serve as lead plaintiff.
- Neutral Sentiment: The reported class action alleges violations of federal securities laws by Anavex and certain officers. The allegations have not been proven, and the announcements do not provide a ruling or settlement. Bronstein Gewirtz and Grossman announcement
- Negative Sentiment: The unusually large number of investor-law-firm notices is creating a litigation overhang and may increase uncertainty about potential legal costs, damages, management attention, and reputational impact. Multiple firms reminded investors that the deadline to seek lead-plaintiff status is November 30, 2026. Howard G. Smith announcement
About Anavex Life Sciences
Anavex Life Sciences Corp. (NASDAQ: AVXL) is a clinical-stage biotechnology company focused on developing pharmaceutical therapies for central nervous system disorders. The company’s research is centered on small-molecule compounds intended to address cellular pathways associated with neurodegeneration and other neurological conditions.
Anavex’s lead product candidate is blarcamesine (ANAVEX2-73), an orally administered investigational therapy designed to activate the sigma-1 receptor and modulate muscarinic receptors.
Featured Stories
- Five stocks we like better than Anavex Life Sciences
- NVIDIA’s Record High Raises a Bigger Question About How Far the Rally Can Run
- A Manufacturing Surprise Could Be a Big Win for These 2 Companies
- What a $1 Billion Chip Deal Says About Amazon’s AI Ambitions
- 3 Stocks Benefiting From AI Demand Just Announced Major Buybacks
Receive News & Ratings for Anavex Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
